The NASDAQ-listed drug maker said the Sptiritus phase 2b trial study of vapendavir in treating moderate to severe asthma sufferers with a rhinovirus infection did not meet its primary endpoint.
The treatment failed to demonstrate a “statistically significant” reduction in asthma symptoms at day 14 of the study for the 264 mg or 528 mg dosages, compared to placebo.
“We are disappointed that the Spirtus trial did not meet its primary endpoint in this patient population,” chief executive Joseph Patti, said.
“There was evidence of an antiviral effect in patients that received vapendavir within the first day following the onset of their symptoms, and as such, we plan to take time to fully analyse the data before making a decision on whether to initiate a study in hematopoietic stem cell transplant patients, where the ability to stop the progression of the rhinovirus infection could be beneficial.”
In early February, Aviragen reported that BTA 585, its drug for the treatment of respiratory syncytial virus infections, flunked in a phase 2a trial.
Shares plunged 34.91% on the NASDAQ in early US trade.